Welcome to our dedicated page for Natera news (Ticker: NTRA), a resource for investors and traders seeking the latest updates and insights on Natera stock.
Natera, Inc. (Symbol: NTRA) is a leading diagnostic and research company based in San Carlos, CA, driven by a commitment to advance the science and application of prenatal testing. In the information age, medical diagnostics have lagged behind in adopting new technologies, but Natera is changing that narrative. The company specializes in preconception and prenatal genetic testing services, providing couples with crucial information throughout the pregnancy journey.
Natera offers a comprehensive range of tests, including Preimplantation Genetic Diagnosis (PGD) for IVF and Non-Invasive Prenatal Testing (NIPT). Their Panorama NIPT is particularly notable for its ability to screen for chromosomal abnormalities in a fetus, even in twin pregnancies, typically through a simple blood draw from the mother. Another significant product is the Horizon Carrier Screening (HCS), which determines carrier status for numerous severe genetic diseases that could be passed on to offspring.
The company's innovative approach leverages advances from the Human Genome Project and is powered by proprietary bioinformatics algorithms. This technology enables highly accurate genetic testing results. Natera's portfolio also includes the Signatera Molecular Residual Disease (MRD) Test, designed to detect circulating tumor DNA in cancer patients, helping to assess molecular residual disease and monitor recurrence. Additionally, the Prospera test assesses organ transplant rejection.
Through its pioneering genetic testing services and experienced genetic counseling, Natera provides valuable insights that help in informed decision-making for pregnancies and medical conditions. The company continues to make significant strides in the field of medical diagnostics, driven by a passion for innovation and excellence.
Natera, Inc. (NASDAQ: NTRA) announced the RenaCARE study, aiming to assess the clinical utility of its Renasight genetic testing panel for chronic kidney disease (CKD). The study is projected to enroll 2,000 patients by Q2 2022, building on previous research showing that 89% of patients with positive multi-gene tests had actionable clinical implications. With 1,600 patients enrolled across 25 sites, the study will evaluate the impact of genetic findings on patient care management, satisfaction, and genetic literacy, contributing to evidence on the value of genetic testing in CKD.
Natera, Inc. (NASDAQ: NTRA) announced findings from a significant real-world study demonstrating a 21.1% positive yield for genetic findings using its Renasight™ test in chronic kidney disease (CKD) patients. Out of 1,007 patient samples analyzed, 220 positive results were identified across 48 genes, underscoring Renasight's effectiveness for genetic diagnoses in nephrology. The study highlights Renasight's potential to aid in clinical management and inform treatment options for the approximately 37 million U.S. adults affected by CKD.
Natera, Inc. (NASDAQ: NTRA) announced the publication of its DEDUCE study in the Journal of Heart and Lung Transplantation, demonstrating the effectiveness of its Prospera™ Heart test in assessing acute rejection in heart transplant patients. The study analyzed 703 prospective samples, achieving an impressive AUC of 0.86. The test shows potential to replace invasive biopsies and is backed by further trials, including NIH-supported studies anticipated to involve over 775 patients. This advancement highlights Natera's commitment to precision in heart transplant care.
Natera, Inc. (NASDAQ: NTRA) announced new findings regarding its Signatera personalized molecular residual disease test at the American Association for Cancer Research annual meeting held from April 8-13, 2022. The data focuses on triple negative breast cancer (TNBC) and high-risk hormone receptor-positive/HER2-negative patients. Key results include a significant correlation between detectable circulating tumor DNA (ctDNA) post-surgery and poor outcomes, with a lead time of up to 30 months before recurrence. This reinforces Signatera's role in enhancing patient management for breast cancer.
Natera, Inc. (NASDAQ: NTRA) announced the publication of the VALID study, validating its Prospera™ Lung donor-derived cell-free DNA (dd-cfDNA) test for assessing lung transplant rejection. The study analyzed 195 biopsy-matched samples, demonstrating the test's robust performance, with a 0.91 AUC for acute rejection against stable cases. Already in use at 25% of U.S. lung transplant centers, the Prospera test promises improved patient outcomes in lung transplantation. The study was published in Transplant Direct.
Natera, Inc. (NASDAQ: NTRA) announced the appointment of Sangeeta Bhorade, M.D., as the new vice president of organ health medical affairs.
Dr. Bhorade brings over 27 years of experience, including her role at the University of Chicago and Northwestern University. This addition follows other key hires, enhancing Natera's leadership in organ health. Her expertise is expected to drive innovation and improve patient care. With this new leadership, Natera aims to strengthen its position in the organ health sector.
Natera, Inc. (NASDAQ: NTRA) announced a study published in Transplantation Proceedings that highlights the significance of total cell-free DNA (cfDNA) testing in kidney transplant recipients hospitalized with COVID-19. Using its Prospera™ test, the study reveals that elevated total cfDNA can obscure donor-derived cfDNA (dd-cfDNA) levels, potentially masking transplant rejection cases. The Prospera test identified two patients whose biopsy-proven rejections were undetected by dd-cfDNA alone. This research underscores the necessity of total cfDNA in understanding graft health amidst COVID-19 challenges.
Natera, a leader in cell-free DNA testing, has been recognized by Fast Company in its annual list of the World's Most Innovative Companies for 2022. The company ranked sixth in the Health category, acknowledged for its Signatera™ MRD test, which effectively monitors therapy response and predicts patient benefit from immunotherapy across various cancer types. This recognition highlights the test's significant impact, particularly after Medicare's approval for its serial use in pan-cancer immunotherapy monitoring.
Eikon Therapeutics has appointed Dr. Roy D. Baynes as Executive Vice President and Chief Medical Officer, effective July 11, 2022. Dr. Baynes, a distinguished oncologist with extensive experience, previously held senior roles at Merck and Amgen, contributing to the development of significant drugs like Keytruda. He will lead the company's clinical research and development, leveraging Eikon's advanced technologies in drug discovery. This appointment aims to strengthen Eikon's ability to deliver innovative therapies for serious illnesses.
Natera, a global leader in cell-free DNA testing, has published a study in Transplantation showing that its Prospera™ technology effectively assesses pancreas graft rejection in simultaneous pancreas-kidney transplants. Conducted at the Hospital Clinic of Barcelona, the study involved 36 transplant recipients and highlighted that the combination of donor-derived cell-free DNA (dd-cfDNA) quantity and fraction significantly outperformed existing biochemical markers, achieving a sensitivity of 85.7% and specificity of 93.7%. This advancement positions Natera for improved clinical outcomes in transplant care.
FAQ
What is the current stock price of Natera (NTRA)?
What is the market cap of Natera (NTRA)?
What does Natera, Inc. specialize in?
Where is Natera, Inc. headquartered?
What is the Panorama Non-Invasive Prenatal Test (NIPT)?
What is the Horizon Carrier Screening (HCS)?
What is the Signatera Molecular Residual Disease (MRD) Test?
What is the purpose of the Prospera test?
How has Natera advanced genetic testing?
Does Natera offer genetic counseling services?
What industries does Natera serve?
What makes Natera's tests unique?
